Magle Chemoswed Holding AB (publ) (STO:MAGLE)

Market Cap	545.73M
Revenue (ttm)	284.88M
Net Income (ttm)	7.79M
Shares Out	20.52M
EPS (ttm)	0.50
PE Ratio	53.74
Forward PE	46.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	320
Average Volume	710
Open	26.00
Previous Close	26.60
Day's Range	26.00 - 26.00
52-Week Range	24.20 - 46.62
Beta	0.49
RSI	46.93
Earnings Date	Aug 1, 2025

About STO:MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 147
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

In 2024, STO:MAGLE's revenue was 240.57 million, an increase of 40.27% compared to the previous year's 171.50 million. Earnings were 11.94 million, a decrease of -1.91%.